NCT07032298View on ClinicalTrials.gov

A Phase I Study of SSGJ-612 in Patients With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 18, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

June 30, 2026

Conditions
Advanced Malignant Tumors
Interventions
DRUG

SSGJ-612

Intravenous injection

Trial Locations (1)

Unknown

RECRUITING

The First Affiliated Hospital of Henan University of Science & Technology, Luoyang

All Listed Sponsors
lead

Shenyang Sunshine Pharmaceutical Co., LTD.

INDUSTRY